Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · October 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07876596). This is a study registration, not published results. Lead sponsor: Shandong Suncadia Medicine Co., Ltd.. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 18 participants (ESTIMATED). Conditions: Breast Cancer. Interventions: DRUG: HRS-8080; DRUG: Rifampicin. Primary outcome measures: Peak concentration (Cmax) , Day 1 to Day 15.; Area under the serum concentration-time curve from time zero to the last quantifiable concentration (AUC0-t) , Day 1 to Day 15.; Area under the serum concentration-time curve from time zero extrapolated to infinity (AUC0-∞) , Day 1 to Day 15.. Brief summary: A single-center, single-arm, open-label, fixed-sequence study is planned to enroll 18 healthy participants (6-9 females). The study consists of a screening period, an observation period, and a safety follow-up period.